Research highlights safety and efficacy of novel treatment option for hypogonadism over 52-week period
LCPN10, a novel oral testosterone undecanoate formulation has been shown to be safe and efficacious for the treatment of hypogonadal patients, according to a study being presented during the 111th Annual Scientific Meeting of the American Urological Association (AUA).
Medical News Today
Source: Society for Endocrinology - Category: Endocrinology Source Type: news